Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms- A Prospective Multi-center Double Blind Randomized Trial
J. Urology 192, 1743-1749, 2014
A recent multi-center double-blind placebo-controlled clinical trial testing LP-09 for the treatment of overactive bladder (OAB) conducted in Taiwan. The study showed a significant decrease in the frequency of urination events as measured in self-reported patient diaries, as well as overactive bladder symptom scales. The chart to the left illustrates the frequency data comparing the treatment group (where LP-09 is labeled as "lipo-BoNT" and the placebo is labeled as "saline"). "events per 3 days" represents the reduction in urination events associated with treatment.
Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study
European Urology, 2014
Single-center placebo-control clinical trial testing Lipo-Tox vs. saline. Intravesical LP-09 instillation effectively reduced urinary frequency episodes one month after treatment in overactive bladder patients without any increase in post-void-residual bladder urine content or risk of urinary tract infection. The chart on the left shows the changes from baseline of several symptom measures (urinary frequency, urinary urgency, urinary urge incontinence (UUI), and overactive bladder symptom scale (OABSS)) associated with LP-09 at one month after treatment.
Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Liposomes
J. Urol. Vol. 182, 786-792, August 2009
LP-09 was successfully able to blunt hyperactivity associated with bladder injury/stimulation in a rat OAB model, compared with the effect of either empty liposomes or botulinum toxin delivered without the use of the liposomal formulation (i.e LP-09). The image to the left shows evidence that the efficacy was related to the classic pathway of botulinum toxin action (i.e. cleaving membrane-bound SNAP-25 proteins). The presence of beta-actin is shown as a control. In this figure, LP-09 is indicated as LPs+BoNT-A, empty liposomes are indicated as LPs, and botulinum toxin in saline is indicated as BoNT-A.